Human Genome Sciences Inc. (HGSI) announced the submission of a Biologics License Application or BLA to the U.S. Food and Drug Administration or FDA for ZALBIN for the treatment of chronic hepatitis C.
The company said the BLA submission includes the results of 2 pivotal Phase 3 clinical trials showing that 900-mcg albinterferon alfa-2b dosed every 2 weeks met its primary endpoint of non-inferiority to peginterferon alfa-2a dosed once each week.
The Phase 3 studies, known as ACHIEVE 1 and ACHIEVE 2/3, evaluated albinterferon alfa-2b vs. peginterferon alfa-2a, in combination with ribavirin, for use in the treatment of interferon-naïve patients with chronic hepatitis C, the company added.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.